

CORRECTION

[View Article Online](#)
[View Journal](#) | [View Issue](#)



Cite this: *Chem. Sci.*, 2020, **11**, 12588

Correction: A straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopes

Hajime Wakui,^a Yoshikazu Tanaka,^b Toyoyuki Ose,^c Isamu Matsumoto,^c Koji Kato,^d Yao Min,^c Taro Tachibana,^e Masaharu Sato,^f Kentaro Naruchi,^f Fayna Garcia Martin,^a Hiroshi Hinou^a and Shin-Ichiro Nishimura^{*a}

DOI: 10.1039/d0sc90254c
rsc.li/chemical-science

Correction for 'A straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopes' by Hajime Wakui *et al.*, *Chem. Sci.*, 2020, **11**, 4999–5006, DOI: 10.1039/D0SC00317D.

The authors regret that part Fig. 1b was missing from the version of Fig. 1 shown in the original article. The correct version of Fig. 1 is presented below.

^aField of Drug Discovery Research, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University, N21 W11, Kita-ku, Sapporo, 001-0021, Japan. E-mail: shin@sci.hokudai.ac.jp

^bGraduate School of Life Sciences, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai 980-8577, Japan

^cField of X-ray Structural Biology, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University, N10 W8, Kita-ku, Sapporo 060-0810, Japan

^dResearch Institute for Interdisciplinary Science and Graduate School of Natural Science and Technology, Okayama University, 3-1-1, Tsushima-naka, Kita-ku, Okayama 700-8530, Japan

^eDepartment of Bioengineering, Graduate School of Engineering, Osaka City University, Sumiyoshi-ku, Osaka 558-8585, Japan

^fMedicinal Chemistry Pharmaceuticals, Co., Ltd., N9 W15, Chuo-ku, Sapporo 060-0009, Japan




Fig. 1 Generation of epitope-defined anti-MUC1 antibodies. (a) A strategy for the generation of antibodies targeting glycopeptidic epitopes by using synthetic glycopeptides designed for the streamlined process from the immunization of "conformational glycopeptidic neoepitopes", antibody selection, and characterization. (b) A list of compounds used in this study. Compound 1 was conjugated with KLH by using the Cys residue (red) or aminoxy-functionalized nanoparticles^{25–27} by using the ketone linker (blue) and used for the immunization. The first screening was performed by ELISA immobilizing compounds 1 and 2 using Cys residue (red) to collect antibodies binding selectively with glycopeptide 1. Compound 3 was used for the co-crystallization with SN-101. Compounds 4–24 were displayed on the microarray by means of the ketone linker (blue) and employed for epitope mapping analysis. Compound 25 was used for the SPR analysis by immobilizing with Cys residue (red).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.